A Multi-Center Phase II study of Ruxolitinib in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma
Study of Ruxolitinib in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAT5353
U.S. Govt. ID: NCT04807777
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the study drug ruxolitinib to see how well the drug works on your disease. This study will also explore potential biomarkers for ruxolitinib by examining your blood and tissue for genes and proteins that can help identify and/or predict whether therapy would benefit someone or not. Your tissue samples contain biomarkers such as proteins. Due to your illness, these proteins can be abnormal. For example, there can be too many proteins, or the proteins may be overactive. These abnormal proteins may promote cancer growth. Testing on your tumor samples allows us to fully study biomarkers and answer questions from health authorities about the way the drugs work in this research project.
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a confirmed diagnosis of metastatic advanced cutaneous squamous cell carcinoma? Yes No
Do you have a history of solid-organ transplant requiring immunosuppression? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162